Please assess the completion status of the following clinical trial:

Trial Title: VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent form~* Men and women ≥ 50 years of age.~* Active predominantly classic subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD (wet Age-Related Macular Degeneration)~* BCVA (best corrected visual acuity) of 20/40 to 20/320 in the study eye~Exclusion Criteria:~* Only one functional eye~* Presence of CNV with an origin other than wAMD~* Any prior ocular or systemic treatment or surgery for wAMD, except dietary supplements or vitamins

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321) (Type: EXPERIMENTAL): Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
- PDT treatments (Type: ACTIVE_COMPARATOR): Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).